Wealth Enhancement Advisory Services LLC Buys 36,066 Shares of Eli Lilly and Company $LLY

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in Eli Lilly by 23.7%, owning 187,931 shares valued at approximately $146.7 million after purchasing an additional 36,066 shares in the second quarter.
• Insider transactions revealed that EVP Daniel Skovronsky and Director Gabrielle Sulzberger made share purchases, with Skovronsky acquiring 1,000 shares at $634.40 each and Sulzberger purchasing 117 shares at $641.18 each.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Eli Lilly, with price targets varying from $875 to $1,050, and the company recently reported a strong quarterly earnings beating estimates.

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 23.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 187,931 shares of the company's stock after buying an additional 36,066 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Eli Lilly and Company were worth $146,712,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. WestEnd Advisors LLC lifted its position in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company in the first quarter valued at about $27,000. Citizens National Bank Trust Department raised its position in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company in the first quarter valued at about $40,000. Finally, Mascagni Wealth Management Inc. bought a new position in Eli Lilly and Company in the fourth quarter valued at about $43,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 1.2%

NYSE LLY traded down $9.41 during trading hours on Friday, hitting $753.52. 7,319,147 shares of the company's stock were exchanged, compared to its average volume of 3,181,974. The stock has a 50-day simple moving average of $738.37 and a 200 day simple moving average of $771.89. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.86. The firm has a market cap of $713.18 billion, a price-to-earnings ratio of 49.25, a PEG ratio of 1.06 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter last year, the firm posted $3.92 earnings per share. The firm's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Insider Transactions at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a research report on Sunday, August 17th. UBS Group decreased their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research note on Friday, August 8th. DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Guggenheim decreased their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th. Finally, Leerink Partnrs cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average price target of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.